Expertise in
1
conditions

Melek K. Eryılmaz

Saraykoy Akyokus Street, 
Saraykoy, TR 
Expertise in
1
conditions
Saraykoy Akyokus Street, 
Saraykoy, TR 

Overview

Melek Eryılmaz practices practicing medicine in Saraykoy, Turkey.

Eryılmaz is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Triple-Negative Breast Cancer, Colorectal Cancer, Secondary Adrenal Insufficiency, and Bloom Syndrome.

They are actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 1 clinical trial.

Locations

Saraykoy Akyokus Street, Saraykoy, 42080, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3

72 Total Publications

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.
Journal: Journal of clinical medicine
Published: June 24, 2026

Frequently Asked Questions about Melek K. Eryılmaz

Is Melek K. Eryılmaz a top-rated expert for Triple-Negative Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Melek K. Eryılmaz is classified as an Advanced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Melek K. Eryılmaz participate in research or clinical trials?

Yes. Melek K. Eryılmaz has published 72 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Melek K. Eryılmaz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Eryılmaz's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile